APOE interacts with age to modify rate of decline in cognitive and brain changes in Alzheimer's disease

Alzheimer's and Dementia

Volumn 10, Issue 3, 2014, Pages 336-348

  Chang, Yu Ling ^a   Fennema Notestine, Christine ^b   Holland, Dominic ^c   McEvoy, Linda K ^b   Stricker, Nikki H ^d,e   Salmon, David P ^c   Dale, Anders M ^b,c   Bondi, Mark W ^b,f  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Alzheimer's disease; APOE genotype; Cognition; Longitudinal; Magnetic resonance imaging; Morphometry

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORPHOMETRICS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK FACTOR; TEMPORAL LOBE; VERY ELDERLY; AGE; BRAIN; CROSS-SECTIONAL STUDY; GENETIC PREDISPOSITION; GENETICS; LONGITUDINAL STUDY; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PSYCHOLOGY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; BRAIN; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS;

EID: 84899631915     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.05.1763     Document Type: Article

References (45)

1. Salmon DP, Bondi MW. Neuropsychological assessment of dementia. Annu Rev Psychol 2009;60:257-82.
2. Bondi MW, Houston WS, Salmon DP, Corey-Bloom J, Katzman R, Thal LJ, et al. Neuropsychological deficits associated with Alzheimer's disease in the very-old: discrepancies in raw vs. standardized scores. J Int Neuropsychol Soc 2003;9:783-95.
3. Stricker NH, Chang YL, Fennema-Notestine C, Delano-Wood L, Salmon DP, Bondi MW, et al. Distinct profiles of brain and cognitive changes in the very old with Alzheimer disease. Neurology 2011; 77:713-21.
4. Holland D, Desikan RS, Dale AM, McEvoy LK. Rates of decline in Alzheimer disease decrease with age. PLoS One 2012;7:e42325.
5. Small BJ, Rosnick CB, Fratiglioni L, Backman L. Apolipoprotein E and cognitive performance: a meta-analysis. Psychol Aging 2004; 19:592-600.
6. Fennema-Notestine C, Panizzon MS, Thompson WR, Chen CH, Eyler LT, Fischl B, et al. Presence of ApoE epsilon4 allele associated with thinner frontal cortex in middle age. J Alzheimers Dis 2011; 26:49-60.
7. Hoyt BD, Massman PJ, Schatschneider C, Cooke N, Doody RS. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. Arch Neurol 2005;62:454-9.
8. Stern Y, Brandt J, Albert M, Jacobs DM, Liu X, Bell K, et al. The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer's disease. Ann Neurol 1997; 41:615-20.
9. Martins CA, Oulhaj A, de Jager CA, Williams JH. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology 2005;65:1888-93.
10. Hirono N, Hashimoto M, Yasuda M, Kazui H, Mori E. Accelerated memory decline in Alzheimer's disease with apolipoprotein epsilon4 allele. J Neuropsychiatry Clin Neurosci 2003;15:354-8.
11. Cosentino S, Scarmeas N, Helzner E, Glymour MM, Brandt J, Albert M, et al. APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology 2008;70:1842-9.
12. Farlow MR, Cyrus PA, Nadel A, Lahiri DK, Brashear A, Gulanski B. Metrifonate treatment of AD: influence of APOE genotype. Neurology 1999;53:2010-6.
13. Kleiman T, Zdanys K, Black B, Rightmer T, Grey M, Garman K, et al. Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis. Dement Geriatr Cogn Disord 2006;22:73-82.
14. Negash S, Greenwood PM, Sunderland T, Parasuraman R, Geda YE, Knopman DS, et al. The influence of apolipoprotein E genotype on visuospatial attention dissipates after age 80. Neuropsychology 2009; 23:81-9.
15. Alzheimer's Disease Neuroimaging Initiative. Available at: http:// www.adni-info.org/Scientists/ Accessed September 8, 2011.
16. Alzheimer's Disease Neuroimaging Initiative. Available at: http:// www.adni-info.org. Accessed September 8, 2011.
17. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2001;74:201-9.
18. HughesCP,BergL,DanzigerWL, CobenLA,MartinRL.Anewclinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-72.
19. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58:1985-92.
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
21. Fennema-Notestine C, Ozyurt IB, Clark CP, Morris S, Bischoff- Grethe A, Bondi MW, et al. Quantitative evaluation of automated skull-stripping methods applied to contemporary and legacy images: effects of diagnosis, bias correction, and slice location. Hum Brain Mapp 2006;27:99-113.
22. Han X, Jovicich J, Salat D, van der Kouwe A, Quinn B, Czanner S, et al. Reliability of MRI-derived measurements of human cerebral cortical thickness: the effects of field strength, scanner upgrade and manufacturer. Neuroimage 2006;32:180-94.
23. Jovicich J, Czanner S, Greve D, Haley E, van der Kouwe A, Gollub R, et al. Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data. Neuroimage 2006;30:436-43.
24. Jack CR Jr., Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 2008; 27:685-91.
25. Alzheimer's Disease Neuroimaging Initiative. Available at: http:// adni.loni.ucla.edu/methods/documents/mri-protocols/ Accessed September 8, 2011.
26. Alzheimer's Disease Neuroimaging Initiative. Sharing Alzheimer's Research Data with the World. Available at: http://adni.loni.ucla. edu. Accessed September 8, 2011.
27. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 1998;17:87-97.
28. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002;33:341-55.
29. Fischl B, van der Kouwe A, Destrieux C, Halgren E, Segonne F, Salat DH, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex 2004;14:11-22.
30. Dale AM, Sereno MI. Improved localization of cortical activity by combining EEG and MEG with MRI cortical surface reconstruction: a linear approach. J Cogn Neurosci 1993;5:162-76.
31. Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis: I. Segmentation and surface reconstruction. Neuroimage 1999;9:179-94.
32. Fischl B, Sereno MI, Dale AM. Cortical surface-based analysis: II. Inflation, flattening, and a surface-based coordinate system. Neuroimage 1999;9:195-207.
33. Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006;31:968-80.
34. Fennema-Notestine C, Hagler DJ Jr., McEvoy LK, Fleisher AS, Wu EH, Karow DS, et al. Structural MRI biomarkers for preclinical and mild Alzheimer's disease. Hum Brain Mapp 2009;30:3238-53.
35. Makris N, Meyer JW, Bates JF, Yeterian EH, Kennedy DN, Caviness VS. MRI-based topographic parcellation of human cerebral white matter and nuclei II: rationale and applications with systematics of cerebral connectivity. Neuroimage 1999;9:18-45.
36. Buckner RL, Head D, Parker J, Fotenos AF, Marcus D, Morris JC, et al. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage 2004;23:724-38.
37. Holland D, Dale AM. Nonlinear registration of longitudinal images and measurement of change in regions of interest. Med Image Anal 2011;15:489-97.
38. Holland D, Brewer JB, Hagler DJ, Fennema-Notestine C, Dale AM. Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 2009; 106:20954-9.
39. Gutierrez-Galve L, Lehmann M, Hobbs NZ, Clarkson MJ, Ridgway GR, Crutch S, et al. Patterns of cortical thickness according to APOE genotype in Alzheimer's disease. Dement Geriatr Cogn Disord 2009;28:476-85.
40. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder (5th edn) (DSM-5). APA, 2013.
41. Jernigan TL, Archibald SL, Fennema-Notestine C, Gamst AC, Stout JC, Bonner J, et al. Effects of age on tissues and regions of the cerebrum and cerebellum. Neurobiol Aging 2001;22:581-94.
42. Bell RD,Winkler EA, Singh I, Sagare AP, Deane R,Wu Z, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012;485:512-6.
43. Austad S. Why women live longer than men: sex differences in longevity. Gender Med 2006;3:79-92.
44. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:270-9.
45. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:263-9.